Morgan Stanley rated the Genmab A/S (NASDAQ: GMAB) stock “an Equal-weight” and gave the company’s common stock a price target of $41. Morgan Stanley’s estimates were contained in a research note released on Tuesday, January 19, 2021. Several other experts on Wall Street have posted such reports regarding the GMAB shares. Other experts at SVB Leerink have the stock’s price target at $35 price; with their rating of the stock is “a Mkt perform.” These scores were published in a research note the firm released on Tuesday, September 08, 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Wall Street analysts tracking the Genmab A/S (NASDAQ: GMAB) stock on daily basis. Out of 24 analysts, 11 deeming the stock a Buy and 1 gave it a rating of OVERWEIGHT. Another 9 recommended that GMAB is a HOLD, while 0 rated it UNDERWEIGHT and the 3 recommended SELL. If we look at the broader picture, the above ratings give the stock an average analyst rating of 2.10.
Genmab A/S has a market valuation of $29.06 billion and last released its earnings reports on 02/24/2021, for the quarterly period ended on 9/29/2020. The company’s revenue for the quarter stood at $1.72 billion. GMAB Company also reported its earnings per share (EPS) as $0.13 for the quarter, which miss consensus estimates by analysts of $0.99 by -$0.86, surprisingly -86.90% lower.
The stock market has more often than not ended up being extremely baffling, catching even some of the more experienced traders by surprise. It happens that even when results are as projected, the market sometimes just takes a sudden turn towards the opposite direction. Often such events lead to doubt and much speculation. At such time, it may pay to keep tabs on a stock’s historical price performance. Useful also would be knowledge of the stock’s trends, both the short term and long-term. Genmab A/S (NASDAQ: GMAB) share prices have increased by 5.65% over the past week, but are up 20.49% over prices posted in the last quarter. Going further back, the stock’s price has tanked 24.38% over the last 6 months but is up 9.03% in year-to-date trading.
A recent spot check on the stock’s support and resistance revealed that the publicly-traded Genmab A/S (NASDAQ: GMAB) shares are trading at a price close to -1.12% lower than its 90-day high. On the other hand, the stock is +33.16% away from its low in the 90-day period. More broadly, GMAB’s current price is -1.12% away from 52-week high. The price is 172.97% above from its 52-week low.
Focusing on the company’s market volatility shows that it has a 1-Week Volatility index of 2.57%, and 1.96% for the month. This stock’s Average True Range (ATR) currently stands at 1.04. The indicator of Volatility helps exhibit the extent to which a stock is likely to plummet or climb when the rest of the market also dips or surges. If a stock has a beta score above 1, then its rate of volatility is high. Figures lower than 1, therefore, means that the stock’s volatility at that particular moment is low.
Shares of the Genmab A/S (NASDAQ: GMAB) dropped by -$0.07 during Tuesday’s regular trading session to climb to $44.33. The company had a daily trading volume of 0.79 million shares, higher than its average intra-day trading volumes of about 475.86K shares.